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and other class IC drugs (such as flecainide) have greater 
potential for triggering sustained ventricular tachycardia 
compared to IA or IB drugs. Propafenone in particular 
has 5-10% overall incidence of proarrhythmia3,4 and is 
prone to causing proarrhythmic effects in patients with 
underlying structural heart disease by slowing conduction 
and creating unfavourable imbalance between conduction 
and refractoriness.5 Propafenone is considered to be 
among first-line treatments for conversion of recent onset 
atrial fibrillation but is contraindicated in patients with 
congestive heart failure, severe systolic dysfunction, 
sinoatrial / atrioventricular / intraventricular disorders of 
impulse conduction or sinus node dysfunction, patients 
with unstable angina, a recent or acute myocardial 
infarction.6 Caution should be taken for all these 
conditions to avoid incessant ventricular tachycardia, 
dramatic decrease in cardiac output and circulatory arrest.  
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The ESC Annual Congress is slated for 27-31/8/2011 in 
Paris 
 
The TCT Annual Conference will be held in San 
Francisco 7-11/11/2011  
 
The AHA Annual Scientific Sessions are scheduled for 
12-16/11/2011 in Orlando 
 
The Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
Reverse remodeling in cardiac resynchronization 
therapy reduces the risk of ventricular 
tachyarrhythmias in the MADIT-CRT trial  
 
The risk for ventricular tachyarrhythmias (VTA) 
(including ventricular tachycardia, ventricular fibrillation 
and ventricular flutter) was assessed in patients receiving 
cardiac resynchronization defribrillator therapy (CRT-D) 
or cardioverter-defribillator therapy (ICD) according to 
echocardiographic findings during 1-year follow-up. It 
was found that high responders to CRT-D (defined as ≥ 
25% reduction in left ventricular end-systolic volume) 
experience a significant 55% reduction in the risk of VTA 
compared with ICD only patients (p<0.001), whereas the 
risk of VTA was not significantly different between low 
responders and ICD-only patients (p=0.21). (Barsheshet 
A et al, J Am Coll Cardiol 2011; 57: 2416-2423) 
 
High-dose atorvastatin does not prevent development 
of atrial fibrillation in patients with prior stroke or 
transient ischemic attack in the SPARCL trial  
Statins are included as upstream therapy for 
prevention of new-onset of atrial fibrillation (AF) in the 
2010 guidelines for the management of AF. The 
SPARCL trial tested the hypothesis that long-term 
treatment with high-dose atorvastatin (80 mg) reduces the 
occurrence of AF in 4731 patients with prior stroke or 
transient ischemic attack who were followed up for a 
median of 4.8 years (patients with prior paroxysmal AF 
were excluded from the trial). It was concluded that the 
time from randomization to first occurrence of new AF 
did not differ between atorvastatin (139 cases of new AF) 
and placebo (122 cases) group (hazard ratio 1.15, 95% CI 
0.90-1.46, P=0.26). (Schwartz GG et al, Am Heart J  
2011; 161: 993-999) 
 
Frequent ventricular pauses in patients receiving 
ticagrelor in the acute phase of acute coronary 
syndromes, according to a sub-analysis of the PLATO 
study 
A prospective continuous electrocardiographic 
assessment was performed within the PLATO study 
comparing ticagrelor and clopidogrel in 2908 patients 
hospitalized with acute coronary syndromes. During the 
first week, ventricular pauses (≥ 3 sec) occurred more 
frequently in patients receiving ticagrelor (relative risk 
1.61, p=0.006) but at 1 month pauses occurred less 
frequently and treatments were similar between groups. It 
is suggested that there are no apparent clinical 
consequences related to the excess in ventricular pauses 
in patients assigned to ticagrelor while the incidence of 
clinical adverse events (including syncope, pacemaker 
placement and cardiac arrest) was no different (Scirica 
BM et al, J Am Coll Cardiol 2011; 57: 1908-1916).  
